Tower Research Capital LLC (Trc) Allovir, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Allovir, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,319 shares of ALVR stock, worth $1,321. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,319
Previous 20,558
88.72%
Holding current value
$1,321
Previous $14,000
92.86%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding ALVR
# of Institutions
63Shares Held
44.6MCall Options Held
14.9KPut Options Held
200-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$6.44 Million0.4% of portfolio
-
Octagon Capital Advisors LP New York, NY11.2MShares$6.39 Million2.19% of portfolio
-
Siren, L.L.C. New York, NY6.6MShares$3.76 Million0.27% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.28MShares$1.87 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.65MShares$1.51 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $53M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...